These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21698600)

  • 1. Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat.
    Hamdy DA; Brocks DR
    J Pharm Sci; 2011 Nov; 100(11):4986-92. PubMed ID: 21698600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
    Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.
    Kuroha M; Azumano A; Kuze Y; Shimoda M; Kokue E
    Drug Metab Dispos; 2002 Jan; 30(1):63-8. PubMed ID: 11744613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High performance liquid chromatographic assay for the simultaneous determination of midazolam and ketoconazole in plasma.
    Hamdy DA; Brocks DR
    J Pharm Biomed Anal; 2010 Nov; 53(3):617-22. PubMed ID: 20537491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat.
    Hamdy DA; Brocks DR
    Xenobiotica; 2011 Feb; 41(2):137-43. PubMed ID: 21058917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
    Ogasawara A; Kume T; Kazama E
    Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonlinear stereoselective pharmacokinetics of ketoconazole in rat after administration of racemate.
    Hamdy DA; Brocks DR
    Chirality; 2009 Jul; 21(7):704-12. PubMed ID: 18988259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.
    Shah SS; Sasaki K; Hayashi Y; Motoyama S; Helmi AR; Khalil WF; Shimoda M
    J Vet Med Sci; 2009 Sep; 71(9):1151-9. PubMed ID: 19801894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs.
    Kuroha M; Shirai Y; Shimoda M
    J Vet Pharmacol Ther; 2004 Oct; 27(5):355-9. PubMed ID: 15500574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models.
    Yang L; Yan C; Zhang F; Jiang B; Gao S; Liang Y; Huang L; Chen W
    Exp Anim; 2018 Feb; 67(1):71-82. PubMed ID: 29129847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats.
    Vuppugalla R; Zhang Y; Chang S; Rodrigues AD; Marathe PH
    Xenobiotica; 2012 Nov; 42(11):1058-68. PubMed ID: 22574883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.
    Kotegawa T; Laurijssens BE; Von Moltke LL; Cotreau MM; Perloff MD; Venkatakrishnan K; Warrington JS; Granda BW; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1228-37. PubMed ID: 12183684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats.
    Tai T; Huang X; Su Y; Ji J; Su Y; Jiang Z; Zhang L
    J Ethnopharmacol; 2014 Mar; 152(2):358-63. PubMed ID: 24486211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.
    Guo Y; Lucksiri A; Dickinson GL; Vuppalanchi RK; Hilligoss JK; Hall SD
    Clin Pharmacol Ther; 2020 Jan; 107(1):246-256. PubMed ID: 31356678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of posaconazole in rat.
    Khalil HA; Elnaggar MM; Belal TS; El-Yazbi AF; Hamdy DA
    Eur J Pharm Sci; 2016 Aug; 91():190-5. PubMed ID: 27178487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat.
    Brocks DR; Ala S; Aliabadi HM
    Biopharm Drug Dispos; 2006 Jan; 27(1):7-16. PubMed ID: 16278928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A.
    Zhu XH; Jiao JJ; Zhang CL; Lou JS; Liu CX
    Lab Anim; 2009 Jul; 43(3):284-90. PubMed ID: 19237454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.